Ramón y Cajal Health Research Institute (IRYCIS)

Address Ctra. Colmenar Viejo Km 9,100
28034 – Madrid
Spain
Platforms Biomarkers, Vaccines

The Ramón y Cajal Health Research Institute (IRYCIS) is the result of the association of five different entities; i) University Hospital Ramón y Cajal, which is the heart of our institute; ii) the Biomedical Research Foundation of the Hospital, giving support to all the research and innovation activities; iii) Alcalá de Henares University, that gives the ‘university’ character to the Hospital; and iv) two of the most important universities of Spain, Complutense University of Madrid and Autónoma University of Madrid, contributing with some associated research groups from different faculties (Biology, Medicine, Chemistry, Physics, etc)

In our name, in the heart of our acronym and in our logo we exhibit our pride to feel followers of the biomedical research path opened by Dr. Santiago Ramón y Cajal.

Outstanding history of medical research

The core of our Institute, University Hospital Ramón y Cajal, has an outstanding history of medical research, which has been developed over the last forty years in cooperation with various national and international institutions. We believe that we are now prepared not only to be officially recognized for the poles of growth of biomedical research, but also to become an institutional framework capable of making our investigation a significant element in the scientific and economic development of Spain. To do this we have become a Health Research Institute.

On the way to the IRYCIS consolidation, we have noble and faithful companions that provide us support and encouragement: the Madrid Health Service (SERMAS) and the National Health Institute Carlos III of the Ministry of Economy and Competitiveness, to which we wish to express our deepest gratitude.

Five scientific areas

IRYCIS research is organized in five scientific areas: 1. Neuroscience and Sense Organs; 2. Microbiology, Immunology and Infection; 3. Chronic Diseases and Cancer; 4. Epidemiology and Health Technology; 5. Cardiometabology and Systems Pathology.

All these areas are composed by nearly 30 research groups that have achieved well established scientific and organizational standards and which are in leading positions both in the national and international biomedical research fields.

IRYCIS has also 18 facilities offering technical and scientifically services to our researchers: Animal Facilities and Experimental Surgery; Biobank; Biostatistics; Bioinformatics; Clinical Research and Clinical Trials Unit; Non-Ionizing Studies; Translational Genomics (NGS); Confocal microscopy; Proteomics; Sinaptic Plasticity Characterization; miRNAs-based Biomarkers and Therapeutic Targets; Virology and Molecular Epidemiology of HIV; Histology; Lipids and Lipoproteins; Microarrays; Oligoclonal Bands Determination; Molecular Quantification and Characterization; Aptamers Laboratory.

Common space

IRYCIS enables all its members to share a common space to share ideas and projects in order to ensure convergence of scientific progress towards the needs of our society.

Our people:

  • 600+ people devoted to research
  • 5 research areas
  • 28 research groups
  • 18 research facilities
  • 60+ networks, consortiums and platforms

Our active projects:

  • 700+ clinical trials
  • 300+ public and private projects
  • 14 european projects
  • 50 innovation projects
  • 18 patents and know-how in an exploitation stage

Our publications:

  • 600+ publications per year
  • 3000+ accumulated impact factor
  • 25% first decile papers
  • 52% first quartile papers

Our education:

  • 30+ research seminars per year
  • 60+ courses and scientific events organized per year
  • 800+ hours
  • 6000+ attendants

Contact

Head of the facility
  • Dra Laura García Bermejo
  • Dra Elisa Conde Moreno

Expertise

Technologies
  • Serial analysis of gene expression (SAGE)
  • RT-PCR
  • Microarrays
  • NGS- RNA sequencing
  • Transgenesis of reporter gene
Purposes
  • Research
  • Clinical use
  • Service
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Disease processes research
  • Human and pathogen transcriptomes
  • Non coding RNA analysis (miRNA, lncRNA, sRNA..)
  • Therapeutic development

Features

Collaboration with industry where the institute collaborated with Transcriptomics expertise (in the last 5 years) <10
% of TIME involved in technology/methods development/innovation/intellectual property related to Transcriptomics 40%

Track record

Key opinion leaders
  • Dra Maria Laura García Bermejo
  • Dr Miguel Angel Moreno Pelayo
  • Dra Leticia Olavarrieta Scappini
  • Dr Val Fernández Lanza
  • Dr Jerónimo Fernández Beltrán
Publications

Contact

Head of the facility
  • Dr Alberto Alcázar

Expertise

Technologies
  • Western Blot
  • Isoelectric focusing (IEF)
  • ELISA
  • MALDI-MS
  • Liquid chromatography (HPLC, UHPLC)
Purposes
  • Research
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Expression proteomics
  • Interaction proteomics and protein networks
  • Responses to environment
  • Therapeutic development

Features

Collaboration with industry where the institute collaborated with Proteomics expertise (in the last 5 years) <10
% of TIME involved in technology/methods development/innovation/intellectual property related to Proteomics 10%

Track record

Key opinion leaders
  • Juan Antonio López del Olmo- quantitative proteomics
  • Francesc Canals - biomarkers discovery
Publications

Contact

Head of the facility
  • Dr Óscar Pastor

Expertise

Technologies
  • High performance liquid chromatography (HPLC,UHPLC)
  • MALDI-MS
  • LC-MS
  • Secondary ion mass spectrometry (SIMS)
  • Nuclear magnetic resonance (NMR)
  • Desorption electrospray ionization (DESI)
  • Untargeted metabolomics assays
  • Targeted metabolomic assays
Purposes
  • Research
  • Clinical use
Applications
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Disease processes research
  • Therapeutic development

Features

Collaboration with industry where the institute collaborated with Metabolomics expertise (in the last 5 years) <10
% of TIME involved in technology/methods development/innovation/intellectual property related to Metabolomics 50%

Track record

Key opinion leaders
  • Dr Óscar Pastor - lipidomics
Publications

DATA ANALYSIS for

  • Genomics
  • Proteomics
  • Metabolomics
  • Omics data integration / systems biology

DATA INTERPRETATION for

  • Genomics
  • Proteomics
  • Metabolomics
  • Omics data integration / systems biology

DATA SUBMISSION in to public database

STATISTICS

  • Molecular profiling (omics and others)
  • Expertise in clinical design of experiments, clinical statistics
  • Metadata (patient/sample information)

BIOINFORMATICS

  • Expression profiling with omics for RNAseq, microRNA, other RNA species and proteins
  • Data integration (“Systems biology”)
  • Genetic analysis for Structural variation detection (Genome, Exome) and Prediction of protein function from sequence information
  • Development of new algorithms, e.g. new decision algorithms, new sequence aligners for NGS data, etc.
  • Informatics methods to support clinical decisions (diagnostic, predictive tests)

OMICS INTEGRATION METHODS

  • Published tools (R software, …)
  • Own scripts/software
  • Repository: https://www.r-project.org/

Get in touch

Emanuela Oldoni

Share

Like what you read? Share your thoughts!